表紙
市場調查報告書

女性健康的全球市場:規模,佔有率及趨勢:各用途、地區、市場區隔預測(2019年∼2026年)

Women's Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS), By Region, And Segment Forecasts, 2020 - 2027

出版商 Grand View Research, Inc. 商品編碼 581981
出版日期 內容資訊 英文 130 Pages
商品交期: 2-3個工作天內
價格
女性健康的全球市場:規模,佔有率及趨勢:各用途、地區、市場區隔預測(2019年∼2026年) Women's Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, PCOS), By Region, And Segment Forecasts, 2020 - 2027
出版日期: 2020年02月21日內容資訊: 英文 130 Pages
簡介

球女性健康市場在2019年∼2025年間,預測將以4.2%的年複合成長率擴大,2026年達到546億美元的規模。

本報告提供全球女性健康市場的相關調查,市場趨勢和預測,各醫藥品、用途、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查方法及範圍

  • 市場區隔、範圍
  • 調查方法
  • 資訊採購
  • 資訊或資料分析
  • 市場制定、檢驗
  • 模式詳細內容
  • 第二手資料的清單
  • 調查目的

第2章 摘要整理

第3章 市場變數,趨勢及範圍

  • 市場區隔
  • 洞察及成長預測的製圖
  • 商務環境分析工具
  • 臨床實驗平台分析
  • 近幾年的藥的認證

第4章 市場分析:各類醫藥品

  • 市場規模,預測,趨勢分析

第5章 市場分析:各用途

  • 市場佔有率分析
  • 市場區隔儀表板
  • 市場規模,預測,趨勢分析

第6章 市場分析:各地區

  • 市場佔有率分析
  • 市場區隔儀表板
  • 地區市場概述(市場規模,年複合成長率,主要產業,主要企業,主要趨勢)
  • 市場規模,預測,趨勢分析

第7章 競爭情形

  • 最近的開發及影響分析:主要各打入市場業者
  • 策略架構/競爭的分類(主要創新者,市場領導,新興企業)
  • 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-634-9

The global women's health market size is expected to reach USD 56.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 4.2% over the forecast period. Governments and various private organizations focused on women health across the globe, which is likely to drive the market in the coming years. Coverage plans provided to women is one of the key factors expected to drive the market in developed countries.

In U.S., coverage plans provide preventive services for women without any copayment charges. This includes anemia screening on a routine basis, folic acid supplements for women who may become pregnant, hepatitis B screening, breast cancer screening, and contraception. Healthy People 2020 was established by the Department of Health and Human Services which has a 10-year agenda for improving the health of all Americans.

Initiatives undertaken by countries such as India, Japan, China, Singapore, and Australia are expected to drive the market over the forecast period. For example, in September 2016, Australia's Ministry of Health provided a grant of USD 3.8 million till 2019 to Jean Hailes, a women's health group, to help develop its education and outreach.

Owing to aging and rising incidences of obesity, an increase in prevalence of osteoarthritis (OA) has been witnessed. According to the United Nations, about 10%-15% of all adults aged over 60 have some degree of OA, and the condition is more prevalent in women. According to the CDC, in 2013, back problems were more common in women (30.2%). According to the International Osteoporosis Foundation (IOF), the worldwide prevalence of osteoporosis among women was over 200.0 million in 1990, which is anticipated to reach 680.0 million by 2050.

Further key findings from the study suggest:

On the basis of application, postmenopausal osteoporosis dominated the women's health market in 2019 owing to its increasing prevalence in women over 40 and the major risks associated such as osteoporotic fractures. This leads to an increased demand for treatment to prevent bone loss

Availability of a wide range of drugs for the treatment of postmenopausal osteoporosis is projected to boost the market. These include Fosamax, Actonel, Boniva, Reclast, Evista, and Prolia. In April 2017, the U.S. FDA approved a new drug, Tymlos, to treat postmenopausal osteoporosis. The approval was based on data of an 18-month trial that demonstrated a substantial reduction in the risk of vertebral and non-vertebral fractures

North America held the largest market share in 2019 owing to technological advancements and presence of major market players in the region. Asia Pacific, on the other hand, is expected to witness the highest growth rate over the forecast period

Some of the key players in the women's health market are Bayer AG; Allergan; Merck & Co., Inc.; Teva Pharmaceuticals; Pfizer; Agile Therapeutics; Amgen, Inc.; AstraZeneca, Bristol-Myers Squibb, and Ferring B.V.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Objectives - 1
  • 1.2 Objectives - 2

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Application
    • 2.2.2 Region
  • 2.3 Competitive Insights

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Segmentation
  • 3.2 Penetration & Growth Prospect Mapping
    • 3.2.1 Penetration Analysis
    • 3.2.2 Market Driver Analysis
      • 3.2.2.1 Rising incidence of target disorders
      • 3.2.2.2 Child or early marriages
      • 3.2.2.3 Initiatives by government and various organizations
    • 3.2.3 Market Restraint Analysis
      • 3.2.3.1 Patent expiry of major drugs
      • 3.2.3.2 Lawsuits related to contraceptives
  • 3.3 Women's Health Market: Business Environment Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Pestel Analysis
  • 3.4 Clinical Pipeline Analysis
  • 3.5 Approval of Few Drugs in Recent Years

Chapter 4 Women's Health Market: Drug Analysis

  • 4.1 Market Size & Forecasts and Trend Analyses, 2016 - 2027 for the Drug Segment
    • 4.1.1 Evista
      • 4.1.1.1 Evista Market, 2016 - 2027 (USD Million)
    • 4.1.2 Xgeva
      • 4.1.2.1 Xgeva Market, 2016 - 2027 (USD Million)
    • 4.1.3 Prolia
      • 4.1.3.1 Prolia Market, 2016 - 2027 (USD Million)
    • 4.1.4 Mirena
      • 4.1.4.1 Mirena Market, 2016 - 2027 (USD Million)
    • 4.1.5 Zometa
      • 4.1.5.1 Zometa Market, 2016 - 2027 (USD Million)
    • 4.1.6 Reclast/Aclasta
      • 4.1.6.1 Reclast/Aclasta Market, 2016 - 2027 (USD Million)
    • 4.1.7 Minastrin 24FE
      • 4.1.7.1 Minastrin 24fe Market, 2016 - 2027 (USD Million)
    • 4.1.8 Nuvaring
      • 4.1.8.1 Nuvaring Market, 2016 - 2027 (USD Million)
    • 4.1.9 Forteo
      • 4.1.9.1 Forteo Market, 2016 - 2027 (USD Million)
    • 4.1.10 Premarin
      • 4.1.10.1 Premarin Market, 2016 - 2027 (USD Million)
    • 4.1.11 Actonel
      • 4.1.11.1 Actonel Market, 2016 - 2027 (USD Million)
    • 4.1.12 Ortho-Tri-Cy Lo 28
      • 4.1.12.1 Ortho-Tri-Cy Lo 28 Market, 2016 - 2027 (USD Million)

Chapter 5 Women's Health Market: Application Analysis

  • 5.1 Women's Health Application Market Share Analysis, 2019 & 2027
  • 5.2 Women's Health Application Market: Segment Dashboard:
  • 5.3 Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the Application Segment
    • 5.3.1 Postmenopausal Osteoporosis
      • 5.3.1.1 Postmenopausal Osteoporosis Market, 2016 - 2027 (USD Million)
    • 5.3.2 Hormonal Infertility
      • 5.3.2.1 Hormonal Infertility Market, 2016 - 2027 (USD Million)
    • 5.3.3 Endometriosis
      • 5.3.3.1 Endometriosis Market, 2016 - 2027 (USD Million)
    • 5.3.4 Contraceptives
      • 5.3.4.1 Contraceptives Market, 2016 - 2027 (USD Million)
    • 5.3.5 Menopause
      • 5.3.5.1 Menopause Market, 2016 - 2027 (USD Million)
    • 5.3.6 Polycystic Ovary Syndrome (PCOS)
      • 5.3.6.1 Pcos Market, 2016 - 2027 (USD Million)

Chapter 6 Women's Health Market: Regional Analysis

  • 6.1 Women's Health Regional Market Share Analysis, 2019 & 2027
  • 6.2 Women's Health Regional Market: Segment Dashboard
  • 6.3 Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
  • 6.4 Market Size, & Forecasts, and Trend Analysis, 2016 to 2027
    • 6.4.1 North America
      • 6.4.1.1 North America women's health market, 2016 - 2027 (USD Million)
      • 6.4.1.1.1 U.S.
      • 6.4.1.1.1.1 Regulatory & reimbursement scenario
      • 6.4.1.1.1.2 U.S. women's health market, 2016 - 2027 (USD Million)
      • 6.4.1.1.2 Canada
      • 6.4.1.1.2.1 Regulatory & reimbursement scenario
      • 6.4.1.1.2.2 Canada women's health market, 2016 - 2027 (USD Million)
    • 6.4.2 Europe
      • 6.4.2.1 Europe women's health market, 2016 - 2027 (USD Million)
      • 6.4.2.1.1 U.K.
      • 6.4.2.1.1.1 Regulatory & reimbursement scenario
      • 6.4.2.1.1.2 U.K. women's health market, 2016 - 2027 (USD Million)
      • 6.4.2.1.2 Germany
      • 6.4.2.1.2.1 Regulatory & reimbursement scenario
      • 6.4.2.1.2.2 Germany women's health market, 2016 - 2027 (USD Million)
    • 6.4.3 Asia Pacific
      • 6.4.3.1 Asia Pacific women's health market, 2016 - 2027 (USD Million)
      • 6.4.3.1.1 Japan
      • 6.4.3.1.1.1 Regulatory & reimbursement scenario
      • 6.4.3.1.1.2 Japan women's health market, 2016 - 2027 (USD Million)
      • 6.4.3.1.2 China
      • 6.4.3.1.2.1 Regulatory & reimbursement scenario
      • 6.4.3.1.2.2 China women's health market, 2016 - 2027 (USD Million)
    • 6.4.4 Latin America
      • 6.4.4.1 Latin America women's health market, 2016 - 2027 (USD Million)
      • 6.4.4.1.1 Brazil
      • 6.4.4.1.1.1 Regulatory & reimbursement scenario
      • 6.4.4.1.1.2 Brazil women's health market, 2016 - 2027 (USD Million)
      • 6.4.4.1.2 Mexico
      • 6.4.4.1.2.1 Regulatory & reimbursement scenario
      • 6.4.4.1.2.2 Mexico women's health market, 2016 - 2027 (USD Million)
    • 6.4.5 Middle East And Africa (MEA)
      • 6.4.5.1 MEA women's health market, 2016 - 2027 (USD Million)
      • 6.4.5.1.1 South Africa
      • 6.4.5.1.1.1 Regulatory & reimbursement scenario
      • 6.4.5.1.1.2 South Africa women's health market, 2016 - 2027 (USD Million)

Chapter 7 Competitive Analysis

  • 7.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2 Strategic Framework/ Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • 7.3 Company Profiles
    • 7.3.1 ALLERGAN
      • 7.3.1.1 Company overview
      • 7.3.1.2 Financial performance
      • 7.3.1.3 Product benchmarking
      • 7.3.1.4 Strategic initiatives
      • 7.3.1.5 Swot analysis
    • 7.3.2 BAYER AG
      • 7.3.2.1 Company overview
      • 7.3.2.2 Financial performance
      • 7.3.2.3 Product benchmarking
      • 7.3.2.4 Strategic initiatives
      • 7.3.2.5 Swot analysis
    • 7.3.3 MERCK & CO., INC.
      • 7.3.3.1 Company overview
      • 7.3.3.2 Financial performance
      • 7.3.3.3 Product benchmarking
      • 7.3.3.4 Strategic initiatives
      • 7.3.3.5 Swot analysis
    • 7.3.4 PFIZER, INC.
      • 7.3.4.1 Company overview
      • 7.3.4.2 Financial performance
      • 7.3.4.3 Product benchmarking
      • 7.3.4.4 Strategic initiatives
      • 7.3.4.5 Swot analysis
    • 7.3.5 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 7.3.5.1 Company overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product benchmarking
      • 7.3.5.4 Strategic initiatives
      • 7.3.5.5 Swot analysis
    • 7.3.6 AGILE THERAPEUTICS
      • 7.3.6.1 Company overview
      • 7.3.6.2 Financial performance
      • 7.3.6.3 Product benchmarking
      • 7.3.6.4 Strategic initiatives
    • 7.3.7 AMGEN, INC.
      • 7.3.7.1 Company overview
      • 7.3.7.2 Financial performance
      • 7.3.7.3 Product benchmarking
      • 7.3.7.4 Strategic initiatives
      • 7.3.7.5 Swot analysis
    • 7.3.8 APOTHECUS PHARMACEUTICAL CORP.
      • 7.3.8.1 Company overview
      • 7.3.8.2 Product benchmarking
    • 7.3.9 ASTRAZENECA
      • 7.3.9.1 Company overview
      • 7.3.9.2 Financial performance
      • 7.3.9.3 Product benchmarking
      • 7.3.9.4 Strategic initiatives
      • 7.3.9.5 Swot analysis
    • 7.3.10 BLAIREX LABORATORIES, INC.
      • 7.3.10.1 Company overview
      • 7.3.10.2 Product benchmarking
    • 7.3.11 BRISTOL-MYERS SQUIBB COMPANY
      • 7.3.11.1 Company overview
      • 7.3.11.2 Financial performance
      • 7.3.11.3 Product benchmarking
      • 7.3.11.4 Strategic initiatives
      • 7.3.11.5 Swot analysis
    • 7.3.12 FERRING B.V.
      • 7.3.12.1 Company overview
      • 7.3.12.2 Product benchmarking
      • 7.3.12.3 Strategic initiatives

Chapter 8 Research Methodology & Scope

  • 8.1 Research Methodology
    • 8.1.1 INFORMATION PROCUREMENT
      • 8.1.1.1 Purchased database
      • 8.1.1.2 GVR's internal database
    • 8.1.2 PRIMARY RESEARCH:
  • 8.2 Research Scope And Assumptions
  • 8.3 List To Data Sources

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 North America Women's Health Market, by Country, 2016 - 2027 (USD Million)
  • TABLE 3 North America Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 4 U.S. Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 5 Drug development process in Canada
  • TABLE 6 Canada Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 7 Europe Women's Health Market, by Country, 2016 - 2027 (USD Million)
  • TABLE 8 Europe Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 9 U.K. Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 10 Germany Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 11 Asia Pacific Women's Health Market, by Country, 2016 - 2027 (USD Million)
  • TABLE 12 Asia Pacific Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 13 Japan Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 14 China Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 15 Latin America Women's Health Market, by Country, 2016 - 2027 (USD Million)
  • TABLE 16 Latin America Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 17 Brazil Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 18 Mexico Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 19 MEA Women's Health Market, by Country, 2016 - 2027 (USD Million)
  • TABLE 20 MEA Women's Health Market, by Application, 2016 - 2027 (USD Million)
  • TABLE 21 South Africa Women's Health Market, by Application, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Women's health market outlook, 2019
  • Fig. 9 Market trends & outlook
  • Fig. 10 Women's health market segmentation
  • Fig. 11 Penetration & growth prospect mapping
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Market restraint relevance analysis (Current & future impact)
  • Fig. 14 Porter's Five Forces analysis
  • Fig. 15 PESTEL analysis
  • Fig. 16 Evista market, 2016 - 2027 (USD Million)
  • Fig. 17 Xgeva market, 2016 - 2027 (USD Million)
  • Fig. 18 Prolia market, 2016 - 2027 (USD Million)
  • Fig. 19 Mirena market, 2016 - 2027 (USD Million)
  • Fig. 20 Zometa market, 2016 - 2027 (USD Million)
  • Fig. 21 Reclast/Aclasta market, 2016 - 2027 (USD Million)
  • Fig. 22 Minastrin 24FE market, 2016 - 2027 (USD Million)
  • Fig. 23 NuvaRing market, 2016 - 2027 (USD Million)
  • Fig. 24 Forteo market, 2016 - 2027 (USD Million)
  • Fig. 25 Premarin market, 2016 - 2027 (USD Million)
  • Fig. 26 Actonel market, 2016 - 2027 (USD Million)
  • Fig. 27 Ortho-Tri-Cy LO 28 market, 2016 - 2027 (USD Million)
  • Fig. 28 Women's health application market share analysis, 2019 & 2027
  • Fig. 29 Women's health application market: Segment dashboard
  • Fig. 30 Postmenopausal osteoporosis market, 2016 - 2027 (USD Million)
  • Fig. 31 Hormonal infertility market, 2016 - 2027 (USD Million)
  • Fig. 32 Endometriosis market, 2016 - 2027 (USD Million)
  • Fig. 33 Contraceptives market, 2016 - 2027 (USD Million)
  • Fig. 34 Menopause market, 2016 - 2027 (USD Million)
  • Fig. 35 PCOS market, 2016 - 2027 (USD Million)
  • Fig. 36 Women's health regional market share analysis, 2019 & 2027
  • Fig. 37 Women's health regional market: Segment dashboard
  • Fig. 38 Regional market place: Key takeaways
  • Fig. 39 North America women's health market, 2016 - 2027 (USD Million)
  • Fig. 40 U.S. women's health market, 2016 - 2027 (USD Million)
  • Fig. 41 Canada women's health market, 2016 - 2027 (USD Million)
  • Fig. 42 Europe women's health market, 2016 - 2027 (USD Million)
  • Fig. 43 U.K. women's health market, 2016 - 2027 (USD Million)
  • Fig. 44 Germany women's health market, 2016 - 2027 (USD Million)
  • Fig. 45 Asia Pacific women's health market, 2016 - 2027 (USD Million)
  • Fig. 46 Japan women's health market, 2016 - 2027 (USD Million)
  • Fig. 47 China women's health market, 2016 - 2027 (USD Million)
  • Fig. 48 Latin America women's health market, 2016 - 2027 (USD Million)
  • Fig. 49 Brazil women's health market, 2016 - 2027 (USD Million)
  • Fig. 50 Mexico women's health market, 2016 - 2027 (USD Million)
  • Fig. 51 MEA women's health market, 2016 - 2027 (USD Million)
  • Fig. 52 South Africa women's health market, 2016 - 2027 (USD Million)
  • Fig. 53 Recent developments & impact analysis, by key market participants
  • Fig. 54 Strategy framework